Gold prices slip after rallying on Powell rate cut talk
Cartesian Therapeutics, Inc. (RNAC), a pharmaceutical company currently valued at $270 million, reported the results of its 2025 Annual Meeting of Stockholders held on June 13, 2025. The meeting addressed the election of directors, executive compensation, and the appointment of an independent registered public accounting firm. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 12.3, though it faces profitability challenges.
Approximately 84.31% of the company’s outstanding common stock was present or represented by proxy at the meeting. The stockholders elected three Class III Directors to serve until the 2028 Annual Meeting and until their successors are elected and qualified. The elected directors are Timothy C. Barabe, M.B.A., Carsten Brunn, Ph.D., and Nishan de Silva, M.D., M.B.A. These appointments come as analysts maintain a bullish stance on the stock, with an average price target suggesting significant upside potential. Get deeper insights and 6 additional key ProTips with InvestingPro.
The compensation of the company’s named executive officers was approved on a non-binding, advisory basis. Additionally, the appointment of Ernst & Young LLP as Cartesian Therapeutics’ independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The detailed voting results for each nominee and proposal were provided in the company’s filing. Cartesian Therapeutics, based in Frederick, MD, is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol RNAC. This information is based on a press release statement filed with the SEC.
In other recent news, Cartesian Therapeutics has made several notable announcements that could impact investor decisions. The company has enrolled the first participant in its Phase 3 AURORA trial of Descartes-08, targeting myasthenia gravis patients, marking a significant milestone. Analysts at H.C. Wainwright and BTIG have maintained their Buy ratings on Cartesian, with price targets of $40 and $42, respectively, reflecting confidence in the company’s potential. H.C. Wainwright did, however, lower its price target from $45, emphasizing the importance of long-term data for Descartes-08’s success. BTIG highlighted the treatment’s positive safety profile and potential applicability across multiple conditions, including systemic lupus erythematosus. In another development, Cartesian’s Chief Technology Officer, Dr. Metin Kurtoglu, will transition to a consulting role, effective May 2025, as part of a new agreement. Cantor Fitzgerald also reaffirmed its Overweight rating, maintaining a $22 price target, based on updated financial models and company guidance. These developments reflect Cartesian’s ongoing efforts in advancing its clinical programs and maintaining investor interest.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.